全球叢集性頭痛患者人數分析與預測：2026-2035年

叢集性頭痛的特徵是反覆發作的劇烈單側頭痛，並伴隨顱神經自主神經症狀，如流淚、鼻塞、眼瞼腫脹和臉部出汗。此疾病分為復發型和慢性型，兩者均對生活品質、工作效率和心理健康有顯著影響。透過了解盛行率、發生率、人口分佈、已確診和未確診患者數量、嚴重程度、治療模式以及未來流行病學趨勢，患者分析可為藥物研發、醫療保健規劃和商業決策提供寶貴資訊。

市場促進因素

對該疾病的認知提高

神經科醫生、基層醫療醫生和患者權益組織對叢集性頭痛的認知不斷提高，使得對該疾病的識別率顯著提升，診斷延誤也得以減少。標準化診斷標準的廣泛應用，也提高了對需要特殊治療患者的識別率。

提高診斷準確性

頭痛分類指南的進步以及對叢集性頭痛、偏頭痛和其他原發性頭痛疾病進行區分的準確性的提高，正在推動整個醫療保健系統診斷率的提高。

頭痛專科中心的擴張

專門的頭痛診所和神經科護理中心的建立，使患者更容易獲得專家診斷、全面的疾病管理和預防性治療。

人們對疾病負擔的認知不斷提高

隨著我們對叢集性頭痛相關的重大生理、心理、職業和社會經濟負擔的認知不斷加深，我們看到早期診斷、長期後續觀察和流行病學報告方面都有所改善。

區域趨勢

由於北美擁有先進的神經科護理、專業的頭痛診所、完善的診斷指南以及對該疾病的高度認知，因此北美確診的叢集性頭痛患者數量位居世界前列。

歐洲有大量叢集性頭痛患者，這得益於完善的醫療保健系統、積極的頭痛調查計畫以及日益增多的神經科專科服務。

預計亞太地區確診病例數量成長最快，這主要得益於醫療基礎設施的改善、對頭痛疾病認知的提高、神經科服務的擴展以及流行病學研究參與度的提高。

在拉丁美洲、中東和非洲，隨著醫療保健的現代化、醫生教育的普及以及神經科護理服務的增加，診斷和患者識別正在逐步改善。

本報告檢視了全球叢集性頭痛市場，重點關注患者數量，並分析了疾病和流行病學、市場影響因素、創新和研發趨勢、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析、相關法規和政策、競爭格局以及主要公司的概況。

目錄

第1章：執行摘要

第2章：疾病分析與流行病學

• 疾病概述
  • 叢集性頭痛的定義
  • 疾病分類
  • 病理生理學
  • 病因和危險因子
  • 徵兆和症狀
  • 疾病負擔
• 診斷和臨床評估
  • 診斷標準
  • 鑑別診斷
  • 影像檢查和臨床檢查
  • 嚴重程度評估
• 流行病學分析
  • 過去和現在的患者人數
  • 新確診患者人數
  • 確診患者人數
  • 按性別分類的患者人數
  • 按年齡層別分類的患者人數
  • 復發性叢集性頭痛患者人數
  • 慢性叢集性頭痛患者數
  • 接受治療的患者人數
  • 流行病學預測

第3章 市場動態

• 市場概覽
• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰
• 未滿足的需求
• 新療法的影響
• 波特五力分析
• 價值鏈分析

第4章 商業化與市場進入

• 市場進入概覽
• 還款系統狀態
• 價格分析
• 醫療費用支出趨勢
• 病人准入計劃
• 保險覆蓋範圍趨勢
• 相關利益者分析

第5章：創新與通路展望

• 創新概覽
• 管道概覽
• 管線分析：依開發階段分類
  • 第一階段
  • 第二階段
  • 第三階段
• 管道分析：按作用機制分析
  • CGRP通路抑制劑
  • 基於神經調控的方法
  • 血清素受體促效劑
  • 其他新機制
• 管道分析：按模式
  • 小分子藥物
  • 單株抗體
  • 醫療設備
  • 數位技術與神經調控技術
• 臨床試驗現狀
• 新興技術與創新

第6章 當前治療狀況

• 目前治療模式
• 急性期治療方案
  • 氧氣療法
  • 曲坦
  • 經鼻治療
  • 其他
• 預防和治療方案
  • 鈣通道阻斷劑
  • 皮質類固醇
  • CGRP單株抗體
  • 神經調控療法
  • 其他預防性療法
• 治療流程
• 臨床實踐指南
• 治療中未滿足的需求

第7章 全球叢集性頭痛患者群體：規模與預測

• 市場概覽
• 歷史市場規模分析
• 市場規模預測
• 市場魅力分析
• 更多發展機會
• 以以金額為準的絕對市場機會

第8章 全球叢集性頭痛族群：依人群分類

• 治療類型
  • 急性治療
  • 預防性治療
  • 橋接治療
• 依疾病類型
  • 復發性叢集性頭痛
  • 慢性叢集性頭痛
• 按性別
  • 男人
  • 女士
• 按年齡層
  • 兒童
  • 成人
  • 老年人
• 透過行政途徑
  • 口服
  • 注射
  • 鼻腔
• 醫療環境
  • 醫院
  • 專科診所
  • 居家醫療
  • 其他

第9章 區域分析

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲
  • 市場規模和成長
  • 流行病學導論
  • 需求促進因素
  • 監管概述
  • 競爭優勢

第10章：主要國家分析

• 加拿大
• 德國
• 中國
• 日本
• 印度

第11章 法規與政策概述

• 監管概述
• 美國法律規範
• 歐洲法律規範
• 日本的法律規範
• 印度的法律規範
• 中國的法律規範
• 藥物核准途徑
• 醫療設備認證流程
• 藥物安全監測要求
• 當前醫療技術評估狀況

第12章 競爭格局

• 市佔率分析
• 競爭性標竿分析
• 產品系列分析
• 管道競爭力
• 戰略部署

第13章：公司簡介

• GlaxoSmithKline plc
• Medtronic
• Eli Lilly and Company
• electroCore, Inc.
• Pfizer Inc.
• Grunenthal GmbH
• Viatris Inc.
• Autonomic Technologies Inc.
• Zosano Pharma Corp.
• Bausch Health Companies Inc.

第14章 未來展望

• 未來流行病學趨勢
• 新的治療趨勢
• 創新展望
• 市場成長預測
• 策略建議
• 情境分析

第15章：調查方法

Cluster headache is characterized by recurrent attacks of severe unilateral headache accompanied by cranial autonomic symptoms such as tearing, nasal congestion, eyelid edema, and facial sweating. The condition is classified into episodic and chronic forms, both of which significantly impair quality of life, productivity, and mental health. Patient population analysis provides valuable insights into disease prevalence, incidence, demographic distribution, diagnosed and undiagnosed populations, disease severity, treatment patterns, and future epidemiological trends that support pharmaceutical development, healthcare planning, and commercial decision-making.

Market Drivers

Increasing Disease Awareness

Growing awareness among neurologists, primary care physicians, and patient advocacy organizations is improving recognition of cluster headache and reducing diagnostic delays. Wider adoption of standardized diagnostic criteria is contributing to increased identification of patients requiring specialized treatment.

Improved Diagnostic Accuracy

Advances in headache classification guidelines and greater differentiation between cluster headache, migraine, and other primary headache disorders are increasing diagnosis rates across healthcare systems.

Expansion of Specialist Headache Centers

The establishment of specialized headache clinics and neurological care centers is improving patient access to expert diagnosis, comprehensive disease management, and preventive treatment.

Growing Recognition of Disease Burden

Increasing understanding of the significant physical, psychological, occupational, and socioeconomic burden associated with cluster headache is encouraging earlier diagnosis, long-term follow-up, and improved epidemiological reporting.

Market Restraints

High Rate of Misdiagnosis

Cluster headache is frequently misdiagnosed as migraine, sinus headache, or trigeminal neuralgia, delaying appropriate treatment and resulting in underestimation of the true patient population.

Limited Epidemiological Data

Because cluster headache is a rare disorder, large population-based epidemiological studies remain limited in many countries, creating variability in prevalence estimates.

Limited Access to Specialist Care

Many patients continue to experience delayed diagnosis because of shortages of neurologists, headache specialists, and dedicated headache clinics, particularly in low- and middle-income countries.

Patient Population Insights

The global cluster headache patient population can be segmented by disease subtype, disease severity, age group, gender, diagnosis status, treatment status, and geography.

By disease subtype, the patient population includes episodic cluster headache and chronic cluster headache. Episodic disease accounts for approximately 80% to 90% of diagnosed cases, while chronic cluster headache represents a smaller but more clinically challenging patient population.

By disease severity, patients are categorized into mild, moderate, and severe disease, with severe and chronic cases requiring long-term preventive treatment and specialist neurological care.

By age group, the analysis includes pediatric, adolescent, adult, and geriatric populations. Most patients develop symptoms between 20 and 40 years of age, although pediatric onset is increasingly recognized as diagnosis improves.

By gender, cluster headache affects both men and women. Although men remain more frequently affected, recent studies indicate that the gender gap has narrowed substantially as diagnosis in women has improved.

By diagnosis status, the analysis evaluates diagnosed and undiagnosed patient populations, highlighting continued opportunities to improve disease awareness and diagnostic accuracy.

By treatment status, patients are classified into treated and untreated populations, reflecting differences in healthcare access, specialist referral, and availability of preventive therapies.

Epidemiology Trends

The global cluster headache patient population continues to evolve as diagnosis improves.

Key trends include:

• Increasing diagnosis through improved physician awareness.
• Growing recognition of chronic cluster headache.
• Better differentiation from migraine and other headache disorders.
• Expansion of specialized headache centers.
• Improved epidemiological surveillance and patient registries.
• Greater use of digital headache diaries and remote patient monitoring.
• Rising demand for preventive therapies and multidisciplinary disease management.

Regional Insights

North America represents one of the largest diagnosed cluster headache patient populations because of advanced neurological care, specialized headache clinics, established diagnostic guidelines, and greater disease awareness.

Europe maintains a significant patient population supported by comprehensive healthcare systems, active headache research programs, and expanding access to specialist neurology services.

Asia-Pacific is expected to experience the fastest growth in diagnosed patient numbers owing to improving healthcare infrastructure, increasing awareness of headache disorders, expanding neurological services, and greater participation in epidemiological research.

Latin America and the Middle East & Africa are gradually improving diagnosis and patient identification through healthcare modernization, physician education, and increasing access to neurological care.

Competitive Landscape

Cluster headache patient population analysis supports pharmaceutical companies, biotechnology firms, healthcare providers, academic researchers, and policymakers in evaluating disease burden and future commercial opportunities.

Organizations increasingly utilize epidemiological data for clinical trial planning, patient recruitment, market forecasting, healthcare resource allocation, reimbursement planning, and commercialization strategies. The growing use of real-world evidence, digital headache registries, and electronic health records continues to strengthen patient population assessment.

Future Outlook

The global cluster headache patient population is expected to continue expanding through 2035 as disease awareness improves, diagnostic delays decrease, and access to specialist headache care increases. Advances in digital health, artificial intelligence-assisted diagnosis, wearable monitoring technologies, and real-world evidence are expected to enhance epidemiological surveillance and facilitate earlier diagnosis.

Continued investment in headache research and patient registries will improve understanding of disease burden while supporting development of targeted therapies and optimized healthcare planning.

Conclusion

The global Cluster Headache Patient Population Analysis highlights the growing recognition of cluster headache as a severe neurological disorder with significant clinical and socioeconomic burden. Increasing physician awareness, improved diagnosis, expanding access to specialist care, and better epidemiological surveillance are expected to drive continued growth in the diagnosed patient population. Although challenges related to misdiagnosis, underreporting, and limited access to specialist services remain, advances in neurological care and digital health technologies are expected to improve patient identification and long-term disease management.

Key Benefits of this Report

• Comprehensive analysis of the global cluster headache patient population and epidemiological trends.
• Detailed evaluation of prevalence, incidence, diagnosed, treated, and untreated patient populations.
• Assessment of demographic distribution by age, gender, disease subtype, severity, and geography.
• Insights into disease burden, unmet clinical needs, and future patient growth opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Epidemiology forecasting, patient population estimation, clinical trial planning, market opportunity assessment, healthcare resource planning, investment analysis, commercialization strategy, reimbursement planning, and strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global cluster headache patient population by disease subtype, disease severity, age group, gender, diagnosis status, treatment status, and geography
• Evaluation of prevalence, incidence, diagnosed and undiagnosed populations, treated and untreated populations, and epidemiological trends
• Assessment of demographic characteristics, disease burden, healthcare utilization, diagnostic patterns, and unmet clinical needs
• Analysis of regional epidemiology, patient growth trends, healthcare infrastructure, disease awareness initiatives, and future opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Epidemiology Insights
• 1.3 Treatment Landscape Overview
• 1.4 Major Market Trends
• 1.5 Key Growth Opportunities
• 1.6 Competitive Overview
• 1.7 Future Outlook

2. Disease & Epidemiology Analysis

• 2.1 Disease Overview
  • 2.1.1 Definition of Cluster Headache
  • 2.1.2 Disease Classification
  • 2.1.3 Pathophysiology
  • 2.1.4 Etiology and Risk Factors
  • 2.1.5 Signs and Symptoms
  • 2.1.6 Disease Burden
• 2.2 Diagnosis and Clinical Assessment
  • 2.2.1 Diagnostic Criteria
  • 2.2.2 Differential Diagnosis
  • 2.2.3 Imaging and Laboratory Assessment
  • 2.2.4 Disease Severity Assessment
• 2.3 Epidemiology Analysis
  • 2.3.1 Historical and Current Patient Population
  • 2.3.2 Incident Cases
  • 2.3.3 Diagnosed Patient Population
  • 2.3.4 Gender-wise Patient Population
  • 2.3.5 Age-wise Patient Population
  • 2.3.6 Episodic Cluster Headache Patient Population
  • 2.3.7 Chronic Cluster Headache Patient Population
  • 2.3.8 Treated Patient Population
  • 2.3.9 Epidemiology Forecast

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
• 3.3 Market Restraints
• 3.4 Market Opportunities
• 3.5 Market Challenges
• 3.6 Unmet Needs
• 3.7 Impact of Emerging Therapies
• 3.8 Porter's Five Forces Analysis
• 3.9 Value Chain Analysis

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Pricing Analysis
• 4.4 Healthcare Spending Trends
• 4.5 Patient Access Programs
• 4.6 Insurance Coverage Trends
• 4.7 Stakeholder Analysis

5. Innovation & Pipeline Landscape

• 5.1 Innovation Overview
• 5.2 Pipeline Overview
• 5.3 Pipeline Analysis by Development Stage
  • 5.3.1 Phase I Pipeline
  • 5.3.2 Phase II Pipeline
  • 5.3.3 Phase III Pipeline
  • 5.3.4 Preclinical Pipeline
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Calcitonin Gene-Related Peptide (CGRP) Pathway
  • 5.4.2 Neuromodulation Technologies
  • 5.4.3 Serotonin Receptor Modulators
  • 5.4.4 Other Emerging Mechanisms
• 5.5 Pipeline Analysis by Modality
  • 5.5.1 Small Molecules
  • 5.5.2 Monoclonal Antibodies
  • 5.5.3 Medical Devices
  • 5.5.4 Digital and Neuromodulation Technologies
• 5.6 Clinical Trial Landscape
• 5.7 Emerging Technologies and Innovations

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Treatment Options
  • 6.2.1 Oxygen Therapy
  • 6.2.2 Triptans
  • 6.2.3 Intranasal Therapies
  • 6.2.4 Other Acute Treatments
• 6.3 Preventive Treatment Options
  • 6.3.1 Calcium Channel Blockers
  • 6.3.2 Corticosteroids
  • 6.3.3 CGRP Monoclonal Antibodies
  • 6.3.4 Neuromodulation Therapies
  • 6.3.5 Other Preventive Therapies
• 6.4 Treatment Algorithm
• 6.5 Clinical Practice Guidelines
• 6.6 Unmet Needs in Treatment

7. Global Cluster Headache Patient Population Analysis Size & Forecast

• 7.1 Market Overview
• 7.2 Historical Market Size Analysis
• 7.3 Forecast Market Size Analysis
• 7.4 Market Attractiveness Analysis
• 7.5 Incremental Growth Opportunity
• 7.6 Absolute Dollar Opportunity

8. Global Cluster Headache Patient Population Analysis Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Acute Treatment
  • 8.1.2 Preventive Treatment
  • 8.1.3 Bridge Treatment
• 8.2 By Disease Type
  • 8.2.1 Episodic Cluster Headache
  • 8.2.2 Chronic Cluster Headache
• 8.3 By Gender
  • 8.3.1 Male
  • 8.3.2 Female
• 8.4 By Age Group
  • 8.4.1 Pediatric
  • 8.4.2 Adult
  • 8.4.3 Geriatric
• 8.5 By Route of Administration
  • 8.5.1 Oral
  • 8.5.2 Injectable
  • 8.5.3 Intranasal
• 8.6 By Care Setting
  • 8.6.1 Hospitals
  • 8.6.2 Specialty Clinics
  • 8.6.3 Homecare Settings
  • 8.6.4 Others

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size and Growth
  • 9.1.2 Epidemiology Overview
  • 9.1.3 Demand Drivers
  • 9.1.4 Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth
  • 9.2.2 Epidemiology Overview
  • 9.2.3 Demand Drivers
  • 9.2.4 Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth
  • 9.3.2 Epidemiology Overview
  • 9.3.3 Demand Drivers
  • 9.3.4 Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth
  • 9.4.2 Epidemiology Overview
  • 9.4.3 Demand Drivers
  • 9.4.4 Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth
  • 9.5.2 Epidemiology Overview
  • 9.5.3 Demand Drivers
  • 9.5.4 Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Scenario
  • 10.1.5 Key Companies and Products Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
• 11.3 Europe Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Drug Approval Pathways
• 11.8 Medical Device Approval Pathways
• 11.9 Pharmacovigilance Requirements
• 11.10 Health Technology Assessment Landscape

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Pipeline Competitiveness
• 12.5 Strategic Developments
  • 12.5.1 Collaborations and Partnerships
  • 12.5.2 Mergers and Acquisitions
  • 12.5.3 Licensing Agreements
  • 12.5.4 Product Launches
  • 12.5.5 Clinical Trial Developments

13. Company Profiles

• 13.1 GlaxoSmithKline plc
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products and Generic Names
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Portfolio
  • 13.1.5 Recent Developments
• 13.2 Medtronic
  • 13.2.1 Company Overview
  • 13.2.2 Approved Products and Devices
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Portfolio
  • 13.2.5 Recent Developments
• 13.3 Eli Lilly and Company
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products and Generic Names
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Portfolio
  • 13.3.5 Recent Developments
• 13.4 electroCore, Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products and Devices
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Portfolio
  • 13.4.5 Recent Developments
• 13.5 Pfizer Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Approved Products and Generic Names
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Portfolio
  • 13.5.5 Recent Developments
• 13.6 Grunenthal GmbH
  • 13.6.1 Company Overview
  • 13.6.2 Approved Products and Generic Names
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline Portfolio
  • 13.6.5 Recent Developments
• 13.7 Viatris Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Approved Products and Generic Names
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline Portfolio
  • 13.7.5 Recent Developments
• 13.8 Autonomic Technologies Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Approved Products and Devices
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline Portfolio
  • 13.8.5 Recent Developments
• 13.9 Zosano Pharma Corp.
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products and Generic Names
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Portfolio
  • 13.9.5 Recent Developments
• 13.10 Bausch Health Companies Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Approved Products and Generic Names
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline Portfolio
  • 13.10.5 Recent Developments

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Treatment Trends
• 14.3 Innovation Outlook
• 14.4 Market Growth Projections
• 14.5 Strategic Recommendations
• 14.6 Scenario Analysis

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Primary Research
• 15.4 Secondary Research
• 15.5 Epidemiology Modeling Approach
• 15.6 Market Estimation Methodology
• 15.7 Forecasting Methodology
• 15.8 Data Triangulation
• 15.9 Assumptions and Limitations
• 15.10 Abbreviations and Definitions